Plasma-Derived Hydrogels with Methacrylate Crosslinking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydrogels derived from platelet-rich plasma (PRP) and platelet lysates (PL) face issues with biodegradation and poor mechanical properties, limiting their effectiveness in biomedical applications such as tissue regeneration and cell culture.
Innovation Solution
Development of a novel hydrogel composition where PRP and PL are modified with polymerizable moieties like methacrylates and acrylates, allowing for chemical or physical crosslinking to create a stable, tunable mechanical property matrix, directly linking human-plasma derived elements to polymerizable moieties without intermediates like PEG, and polymerizing in 30-60 seconds, enhancing stability and mechanical properties compared to existing fibrin-based hydrogels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRP and PL are used to form hydrogels for biomedical applications, then biocompatibility and biological activity are improved, but mechanical stability and resistance to biodegradation worsen
Solution Approach 1:
The patent combines PRP/PL with synthetic polymers (PEG, PVA, chitosan, gelatin) to create composite hydrogels that integrate the biocompatibility of natural plasma components with the mechanical strength of synthetic materials. The composite structure allows synergistic properties where the natural components provide biological activity while synthetic components provide structural stability.
Solution Approach 2:
The patent modifies the chemical parameters of PRP/PL by introducing polymerizable groups (methacrylate, acrylate, vinyl) through chemical conjugation. This parameter change enables the plasma components to participate in crosslinked networks, transforming them from simple proteins into structurally active polymers that contribute to both mechanical strength and biological functionality.
2Reliability
If PRP and PL are used to form hydrogels, then biological activity for tissue regeneration is improved, but resistance to enzymatic degradation worsens
Solution Approach 1:
The composite hydrogel structure protects the bioactive plasma components from rapid enzymatic degradation while maintaining their biological activity. The synthetic polymer matrix acts as a protective framework that controls the release and stability of the plasma-derived growth factors and signaling molecules.
Solution Approach 2:
Chemical modification of PRP/PL with stable polymerizable groups changes the degradation parameters of the material. The introduced crosslinkable moieties create more stable chemical bonds that resist enzymatic cleavage while preserving the biological activity of the plasma components.
3Strength
If chemical modification with polymerizable moieties is applied to PRP/PL, then mechanical properties and stability are improved, but complexity of the manufacturing process worsens
Solution Approach 1:
The patent uses small molecule crosslinkers (glutaraldehyde, genipin, EDC/NHS) as intermediaries to facilitate the chemical conjugation between PRP/PL and polymerizable groups. These intermediary agents simplify the manufacturing process by providing well-defined chemical reaction pathways that are easier to control than direct polymer conjugation.
Solution Approach 2:
The manufacturing process performs preliminary chemical modification of PRP/PL to introduce polymerizable groups before hydrogel formation. This preliminary action creates pre-functionalized plasma components that can be directly incorporated into crosslinked networks, simplifying the overall manufacturing steps compared to attempting direct crosslinking of unmodified plasma.
4Strength
If direct crosslinking of plasma components is implemented, then mechanical stability is improved, but loss of biological activity worsens
Solution Approach 1:
The patent carefully controls the degree of substitution and crosslinking density to optimize the balance between mechanical stability and biological activity. By adjusting parameters such as crosslinker concentration, reaction time, and plasma component ratio, the process achieves sufficient mechanical strength while preserving the bioactive conformation and function of plasma proteins.
Solution Approach 2:
The crosslinking is implemented in a controlled manner where only specific regions or functional groups of the plasma proteins are modified. This localized modification approach maintains the overall structural integrity and biological activity domains of the plasma components while providing sufficient crosslinking for mechanical stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting hydrogels exhibit superior mechanical properties, increased stability against enzymatic degradation, and tailored biological responses for cell growth and tissue regeneration, making them suitable for diverse biomedical applications including 3D printing and injectable systems.
Implementation Method 1
modification of blood plasma derived materials with a chemical agent, in particular methacrylates, ethacrylates, thiols, acrylamides, aldehydes, azides, amine reactive groups or cyclic oligosaccharides or combinations thereof, that allows further chemical or physical crosslinking to create a hydrogel
Implementation Method 2
polymerizing in 30-60 seconds
Data Source
AI summary
The present disclosure relates to bioactive hydrogels derived from human blood plasma. More particularly, the disclosure relates to multifunctional materials for cell encapsulation, cell culture platforms, medical treatment apparatus and methods, more particularly, hydrogels derived from human blood components and technologies for use of such materials in research, biomedical treatment, biotech and pharmaceutical industry. The disclosure further relates to 3D printable scaffolds, sponges, foams, fibers, particles, capsules, membranes and injectable systems comprising said hydrogel. Additionally, this disclosure allows for the controlled placement of biologically active components that may be delivered by the hydrogel compositions.